M55 Stock Chart & Stats
€2.88
-€0.03(-0.85%)
At close: 4:00 PM EST
€2.88
-€0.03(-0.85%)
Day’s Range― - ―
52-Week Range€1.14 - €4.22
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€206.74M
Enterprise Value€134.36
Total Cash (Recent Filing)€154.23M
Total Debt (Recent Filing)€36.51M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding63,563,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.83
Price to Sales (P/S)0.68
P/FCF Ratio-1.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.56Price Target Upside93.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.8
Revenue Forecast (FY)€133.07M
Bulls Say, Bears Say
Bulls Say
Asset-light Shift And Non-dilutive CapitalThe $122.5M sale removes capital-intensive manufacturing operations and transfers execution risk to a CDMO while preserving supply via a contract. This materially reduces fixed costs and capex needs, extending runway and allowing capital allocation to R&D and clinical programs over coming quarters.
Expanded Royalty Financing Boosts LiquidityThe additional $60M (aggregate $130M) from the royalty purchase is non-dilutive and provides near-term funding for development. The structure caps the investor's return, preserving upside beyond the capped royalty period, and meaningfully improves financing flexibility without immediate equity issuance.
Advancing Clinical Pipeline With Supportive Safety SignalsMeeting the Stage 1 response threshold and progressing cohorts demonstrates early efficacy and a manageable safety profile, strengthening the ADC program's clinical prospects. ESMO acceptance increases scientific validation and may improve partner/commercial interest over the medium term.
Bears Say
Sustained Negative Cash FlowPersistent large operating and free cash outflows indicate ongoing funding needs to support R&D and trials. With free cash flow tracking net losses closely, the company lacks internal cash generation to self-fund development, increasing reliance on external financing or asset monetizations over months.
Thin Equity Base And Higher LeverageElevated leverage relative to a thin equity cushion reduces financial flexibility and raises refinancing and covenant risks. Continued losses could force dilutive capital raises or additional asset sales, constraining strategic options and increasing long-term funding costs for pipeline progression.
Persistent Operating Losses And Negative MarginsDespite revenue growth and healthy gross margins, operating expenses keep EBIT and EBITDA deeply negative. Without durable margin improvement or meaningful revenue inflection from partnered products, the operating model is unsustainable without recurring external funding over the medium term.
MacroGenics News
M55 FAQ
What was MacroGenics Inc’s price range in the past 12 months?
MacroGenics Inc lowest stock price was €1.14 and its highest was €4.22 in the past 12 months.
What is MacroGenics Inc’s market cap?
MacroGenics Inc’s market cap is €206.74M.
When is MacroGenics Inc’s upcoming earnings report date?
MacroGenics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 17 days.
How were MacroGenics Inc’s earnings last quarter?
MacroGenics Inc released its earnings results on May 13, 2026. The company reported -€0.509 earnings per share for the quarter, missing the consensus estimate of -€0.504 by -€0.005.
Is MacroGenics Inc overvalued?
According to Wall Street analysts MacroGenics Inc’s price is currently Undervalued.
Does MacroGenics Inc pay dividends?
MacroGenics Inc does not currently pay dividends.
What is MacroGenics Inc’s EPS estimate?
MacroGenics Inc’s EPS estimate is -0.07.
How many shares outstanding does MacroGenics Inc have?
MacroGenics Inc has 63,563,120 shares outstanding.
What happened to MacroGenics Inc’s price movement after its last earnings report?
MacroGenics Inc reported an EPS of -€0.509 in its last earnings report, missing expectations of -€0.504. Following the earnings report the stock price went up 8.511%.
Which hedge fund is a major shareholder of MacroGenics Inc?
Currently, no hedge funds are holding shares in DE:M55
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.56 (93.15% Upside)
€5.56 (93.15% Upside)
Blogger Sentiment
Neutral
DE:M55 Sentiment 50%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
M55 Stock 12 Month Forecast
Average Price Target
€5.56
▲(93.15% Upside)